ClinicalTrials.gg

Program

SHR-2173

A development code. Also written as “SHR-2173 injection” and “SHR-2173 Injection”.

In Jiangsu HengRui Medicine's pipeline, IFNAR1/TACI. Its studies are mostly in Lupus Erythematosus, Systemic · Myasthenia Gravis · Purpura, Thrombocytopenic, Idiopathic · Glomerulonephritis, IGA · Glomerulonephritis, Membranous, led by Jiangsu HengRui Medicine.

Furthest: phase 2, since Nov 13, 20258 company-led studies, 6 open or runningNext primary completion: Apr 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Jiangsu HengRui Medicine86 open or runningphase 2since Nov 13, 2025Apr 8, 2025Apr 2027phase 2 · NCT07354932
  • Named in Jiangsu HengRui Medicine’s own pipeline as SHR-2173, phase 3, as of Jul 31, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Apr 8, 2025First study: phase 1 study in Lupus Erythematosus, SystemicFirst studyNCT06955598 · 30 enrolled · China
  2. May 15, 2025Phase 1 study in Healthy VolunteersNCT06995001 · 35 enrolled · China
  3. Sep 26, 2025Phase 1 study in Purpura, Thrombocytopenic, IdiopathicNCT07206758 · 10 planned · China
  4. Nov 13, 20253 phase 2 studiesNCT07229742, NCT07289763, NCT07299422
  5. Jan 12, 2026Phase 2 study in Glomerulonephritis, IGANCT07354932 · 84 planned · China
  6. May 20, 2026Phase 2 study in Myasthenia GravisNCT07622342 · 60 planned · China

Ahead

  1. Apr 2027Primary completion: phase 2 study in Glomerulonephritis, IGANCT07354932
  2. Jun 2027Primary completion: phase 2 study in Active Lupus NephritisNCT07229742
  3. Aug 2027Primary completion: phase 2 study in Primary Membranous NephropathyNCT07289763
  4. Sep 2027Primary completion: phase 2 study in Myasthenia GravisNCT07622342

TargetBeta

“IFNAR1/TACI”the company's pipeline, read by Claude · source

Studies

All 8 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07622342Myasthenia Gravis · China2RecruitingSep 202760
NCT07354932Glomerulonephritis, IGA · China2RecruitingApr 202784
NCT07299422Lupus Erythematosus, Systemic · China2RecruitingMar 2028248
NCT07289763Primary Membranous Nephropathy · China2RecruitingAug 202775
NCT07229742Active Lupus Nephritis · China2RecruitingJun 202751
NCT07206758Purpura, Thrombocytopenic, Idiopathic · China1RecruitingJun 202610
NCT06995001Healthy Volunteers · China1CompletedNov 28, 202435
NCT06955598Lupus Erythematosus, Systemic · China1CompletedNov 10, 202530

How it is read

Names in the registry

  • “SHR-2173 injection”, 8 entries
  • “SHR-2173 Injection”, 3 entries
  • “SHR-2173”, 2 entries

Codes read as this program: SHR2173.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.